From: Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
Cell Viability
[% of Untreated Control]
DOX
[10 μM]
MMC
4-HPR
[5 μM]
5-FU
[1 mM]
No TM
70.7%
73.0%
83.1%
78.3%
With TM, 30 μM
20.9%
48.2%
40.3%
Cytotoxicity Increase
2.5 fold
1.6 fold
2.9 fold
1.9 fold